Status:
TERMINATED
Lenalidomide Adherence in Older Adults
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Alliance for Clinical Trials in Oncology
Conditions:
Multiple Myeloma
Eligibility:
All Genders
65+ years
Brief Summary
To describe patterns of adherence and pilot baseline measures to investigate factors associated with lower adherence to lenalidomide in older adults with myeloma.
Eligibility Criteria
Inclusion
- Age ≥65
- Receiving lenalidomide for treatment of multiple myeloma.
- Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
- Able to read and understand English.
- Able to understand and willing to sign an IRB-approved written informed consent document.
Exclusion
- Estimated life expectancy \<6 months.
- Anticipated duration of lenalidomide therapy \<3 months.
- Residing in a nursing facility where their medications are administered to them OR patient reports they do not self-administer their own medications.
Key Trial Info
Start Date :
December 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03779555
Start Date
December 13 2019
End Date
August 31 2020
Last Update
October 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110